Vor Biopharma Files 8-K: Regulation FD & Financials

Ticker: VOR · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1817229

Vor Biopharma Inc. 8-K Filing Summary
FieldDetail
CompanyVor Biopharma Inc. (VOR)
Form Type8-K
Filed DateSep 2, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-statements, regulation-fd

TL;DR

Vor Biopharma dropped an 8-K on Sept 2nd covering Reg FD and financials. Check it out.

AI Summary

Vor Biopharma Inc. filed an 8-K on September 2, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware with its principal executive offices in Boston, MA, operates in the Biological Products sector.

Why It Matters

This filing provides important updates on regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of financial statements and regulatory disclosures, not indicating any immediate operational or financial distress.

Key Numbers

  • 001-39979 — Commission File Number (Identifies the company's SEC filing history.)
  • 81-1591163 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

  • Vor Biopharma Inc. (company) — Registrant
  • September 2, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Boston, Massachusetts (location) — Address of Principal Executive Offices
  • 02116 (zip_code) — Zip Code of Principal Executive Offices

FAQ

What specific events triggered the Regulation FD Disclosure?

The filing does not specify the exact events triggering the Regulation FD Disclosure, only that it is being reported.

What period do the Financial Statements and Exhibits cover?

The filing indicates 'Financial Statements and Exhibits' as an item, but the specific period covered is not detailed in the provided text.

Has Vor Biopharma Inc. changed its principal executive offices recently?

The filing lists '500 Boylston Street, Suite 1350, Boston, Massachusetts 02116' as the Address of Principal Executive Offices and mentions 'Former Address, if Changed Since', implying a potential change, but the former address is not fully provided.

What is the Standard Industrial Classification for Vor Biopharma Inc.?

The Standard Industrial Classification for Vor Biopharma Inc. is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.

What is the fiscal year end for Vor Biopharma Inc.?

The fiscal year end for Vor Biopharma Inc. is December 31 (1231).

Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-09-02 10:43:08

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated September 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 2, 2025 Vor Biopharma Inc. By: /s/ Jean-Paul Kress Name: Jean-Paul Kress Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.